| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Case of Non–Small-cell Lung Cancer in a Patient With Neurofibromatosis Type 1
|
O’Neill, Robert S.
|
|
|
21 |
4 |
p. e261-e264
|
artikel
|
| 2 |
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy
|
Weissferdt, Annikka
|
|
|
21 |
4 |
p. 341-348
|
artikel
|
| 3 |
A Preliminary Study of Adoptive T-cell Transfer Therapy for Patients With Non–Small-cell Lung Adenocarcinoma With Brain Metastasis: A Case Report of 3 Patients
|
Wang, Hailong
|
|
|
21 |
4 |
p. e270-e273
|
artikel
|
| 4 |
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
|
Hosoya, Kazutaka
|
|
|
21 |
4 |
p. e315-e328
|
artikel
|
| 5 |
A Subsolid Nodules Imaging Reporting System (SSN-IRS) for Classifying 3 Subtypes of Pulmonary Adenocarcinoma
|
Cui, Xiaonan
|
|
|
21 |
4 |
p. 314-325.e4
|
artikel
|
| 6 |
Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy
|
Johns, Andrew C.
|
|
|
21 |
4 |
p. e243-e245
|
artikel
|
| 7 |
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes
|
Lau, Brandon
|
|
|
21 |
4 |
p. 378-383.e1
|
artikel
|
| 8 |
Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non–Small-Cell Lung Cancer
|
Pizarro, Gonzalo
|
|
|
21 |
4 |
p. e250-e254
|
artikel
|
| 9 |
Corrigendum
|
|
|
|
21 |
4 |
p. e238
|
artikel
|
| 10 |
Corrigendum
|
|
|
|
21 |
4 |
p. e239
|
artikel
|
| 11 |
Corrigendum
|
|
|
|
21 |
4 |
p. e233
|
artikel
|
| 12 |
Corrigendum
|
|
|
|
21 |
4 |
p. e235-e237
|
artikel
|
| 13 |
Corrigendum
|
|
|
|
21 |
4 |
p. e234
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
21 |
4 |
p. A1
|
artikel
|
| 15 |
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
|
Prelaj, Arsela
|
|
|
21 |
4 |
p. 365-377.e5
|
artikel
|
| 16 |
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group
|
Forde, Patrick M.
|
|
|
21 |
4 |
p. 295-307
|
artikel
|
| 17 |
Factors Associated With Survival in Complete Pathologic Response Non–Small Cell Lung Cancer
|
Martinez-Meehan, Deirdre
|
|
|
21 |
4 |
p. 349-356
|
artikel
|
| 18 |
Hazards of Recurrence, Second Primary, or Other Tumor at Ten Years After Surgery for Non–Small-Cell Lung Cancer
|
Fink-Neuboeck, Nicole
|
|
|
21 |
4 |
p. 333-340
|
artikel
|
| 19 |
Immune Checkpoint Inhibitor-induced Fatal Myositis in a Patient With Squamous Cell Carcinoma and a History of Thymoma
|
Luecke, Eva
|
|
|
21 |
4 |
p. e246-e249
|
artikel
|
| 20 |
Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma
|
Verma, Vivek
|
|
|
21 |
4 |
p. e274-e285
|
artikel
|
| 21 |
KRAS and BRAF Double Mutations and Functional Classes of BRAF Mutations in Non–small-cell Lung Cancers
|
Bourhis, Amélie
|
|
|
21 |
4 |
p. e240-e242
|
artikel
|
| 22 |
Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients
|
Rajaram, Ravi
|
|
|
21 |
4 |
p. e294-e301
|
artikel
|
| 23 |
Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non–Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations
|
Baek, Jae
|
|
|
21 |
4 |
p. e265-e269
|
artikel
|
| 24 |
Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non–Small-Cell Lung Cancer
|
Ahmed, Tamjeed
|
|
|
21 |
4 |
p. e286-e293
|
artikel
|
| 25 |
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report
|
Gaudreau, Pierre-Olivier
|
|
|
21 |
4 |
p. 384-388
|
artikel
|
| 26 |
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy
|
Arnold, Susanne M.
|
|
|
21 |
4 |
p. 357-364.e7
|
artikel
|
| 27 |
Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer
|
Handa, Yoshinori
|
|
|
21 |
4 |
p. e302-e314
|
artikel
|
| 28 |
Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation
|
Yang, Xue
|
|
|
21 |
4 |
p. e258-e260
|
artikel
|
| 29 |
Table of Contents
|
|
|
|
21 |
4 |
p. A3-A4, A7-A8
|
artikel
|
| 30 |
Temporal Heterogeneity of Resistance Mechanisms to EGFR-TKI Identified in a Patient With Lung Adenocarcinoma and Sarcomatoid Transformation
|
Zheng, Jinyang
|
|
|
21 |
4 |
p. e255-e257
|
artikel
|
| 31 |
The Story of Angiogenesis Inhibitors in Non–small-cell Lung Cancer: The Past, Present, and Future
|
Shukla, Nikhil Atul
|
|
|
21 |
4 |
p. 308-313
|
artikel
|
| 32 |
Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial
|
Gerber, David E.
|
|
|
21 |
4 |
p. 326-332
|
artikel
|
Tijdschrift beschrijving